Background: Hair loss is a serious health concern, with individuals having to bear the associated psychological impact of the condition. Alopecia has been linked to emotional and psychological anguish in relationships, career, and personal life. Objective: This study aimed to elucidate the intricate association, prevalence, and impact of hair loss with anxiety disorders, distinguished from other psychological impacts of alopecia. Methods: The current review and meta-analysis were performed in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) framework. A comprehensive search was performed using the Cochrane, PubMed, and Google Scholar electronic databases studies published in English and conducted between January 2014 and September 2024. Statistical analysis was performed using STATA version 16.0 (StataCorp LLC), and the Newcastle-Ottawa Scale and RoB 2 tools were used for critical quality appraisal. Results: A total of 24 eligible articles were included in the current study, with a cumulative of 5553 patients presenting with 1 or more forms of hair loss. Anxiety disorder was significantly prevalent among patients with alopecia event rate (ER) 0.47 (95% CI: 0.39–0.54). Anxiety severity analysis also showed a significant relationship between anxiety and hair loss, with ERs of 0.35 (95% CI: 0.10–0.60), 0.15 (95% CI: 0.01–0.29), and 0.05 (95% CI: 0.03–0.29), respectively. Statistical significance was also demonstrated by a mean HADS-A score of 7.87 (95% CI: 6.85–8.88). However, considerable heterogeneity was observed in various statistical analyses. Conclusion: In summary, our study showed that among people with hair loss-related diseases, alopecia was substantially linked to anxiety disorders, with the frequency of anxiety among those affected being noticeably higher.

Background: Graying is an inherent and unavoidable consequence of the aging process, impacting individuals of all genders. There are limited studies in Saudi Arabia that have examined the prevalence and predictors of premature graying of hair (PGH). Objectives: This study aims to explore the prevalence and predictors of PGH before the age of 30 among the population of Saudi Arabia. Methods: This is a cross‐sectional online survey that was conducted between July 2023 and February 2024 in Saudi Arabia. Binary logistic regression analysis was used to identify risk factors of having gray hair before the age of 30. Results: A total of 1193 participants were involved in this study. A significant portion of respondents reported having gray hair before the age of 30 (55.9%). The younger population (younger than 44 years), smokers, and those who have comorbidities, have anxiety, have depression, have a family history of gray hair before the age of 30 years, have a dry scalp, suffer from vitamin or mineral deficiencies, have hair loss due to immune diseases (such as alopecia), and use minoxidil or rosemary for hair loss were more likely to have gray hair before the age of 30 years ( p < 0.05). Conclusion: This study highlighted the high prevalence rate and associated predictors of PGH in Saudi Arabia. Identified predictors include genetic, health, and lifestyle factors. Healthcare professionals and decision makers are advised to promote the awareness of the general public on its risk factors to enhance the prevention of PGH. Public health initiatives include campaigns on smoking cessation, healthy nutrition, and mental health.

Bullous pemphigoid (BP) is a chronic autoimmune blistering disorder that primarily affects older adults. While typically associated with tense bullae, its urticarial phase presents diagnostic challenges due to its nonspecific features, often mimicking other pruritic dermatoses. This report presents a unique case of urticarial phase BP triggered by influenza vaccination in a 58-year-old male, with a clinical course marked by widespread intensely pruritic annular erythematous plaques. Notably, no vesicles, bullae, or erosions were observed during the early phase. Histopathological analysis revealed subepidermal eosinophilic infiltration and characteristic direct immunofluorescence findings, confirming the diagnosis. Treatment with systemic corticosteroids and topical therapies resulted in clinical remission. This case contributes to the growing evidence of vaccine-triggered autoimmune diseases, highlighting potential mechanisms such as molecular mimicry and immune dysregulation. By comparing this case with previous reports, we underscore the importance of recognizing vaccination as a potential BP trigger. Clinicians should maintain vigilance in diagnosing and managing this rare but significant complication. Further research is needed to elucidate the immunopathogenesis and establish guidelines for vaccination in high-risk individuals.

Introduction: Adalimumab is a TNF-α antagonist used to treat psoriasis and rheumatologic conditions; it can rarely cause hepatotoxicity manifesting as elevated liver enzymes. Case Presentation: Here, we present a case of a 24-year-old female with chronic plaque psoriasis with no history of liver disease or any risk factor for liver disease who developed a drug-induced liver injury upon treatment initiation with Adalimumab. This case report highlights the importance of monitoring liver function tests in patients receiving Adalimumab, early recognition, and prompt medication dosage adjustment or discontinuation. Early diagnosis and treatment of chronic plaque psoriasis is critical for improving prognosis, especially in the case of increased risk factors of liver disease due to the administration of Adalimumab. Conclusion: Our case presented a patient with no history of liver disease; however, she developed a drug-induced liver injury. Therefore, this case report is the first to emphasize the need for early recognition of LFTs upon Adalimumab administration, and prompt medication dosage adjustment or discontinuation is essential in patients receiving Adalimumab.